Acute high-alitude illnesses
Conditions
Interventions
RIPC Group + Acetazolamide Group:RIPC (cuff pressure 180 mmHg) will be initiated four times daily by 72 hours prior to plateau entry and 125 mg acetazolamide orally twice daily will be initiated 48 ho
Sham control Group:Sham RIPC (cuff pressure 50 mmHg) will be initiated four times daily 72 hours prior to plateau entry and oral acetazolamide 125 mg twice daily starting 48 hours prior to plateau ent
Sponsors
Ya'an People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Part One: (1) Age 18 and above; (2) Immigrant residents in the western Sichuan Plateau region (>2500 meters) who have been living there for 2 years or more; (3) The permanent residents of the lowlands in western Sichuan ( 2500 meters) in the following 2 weeks; (3) Permanent residence at an altitude of less than 2500 meters and have not traveled to high-altitude areas in the last 2 years; (4) Signed informed consent, able to cooperate with the examination and complete the study.
Exclusion criteria
Exclusion criteria: Part One: (1) Suffering from serious chronic diseases such as cardiovascular disease, respiratory system disease, endocrine disease, etc; (2) Chronic headache and dizziness symptoms in the past 3 months; (3) History of migraine and cluster headache; (4) Have a history of acute infectious diseases or other acute diseases in the past month; (5) Pregnant or lactating women; (6) Have participated in other intervention studies. Part Two and Three: (1) History of travel to high-altitude areas (> 2500 meters) within the last two years; (2) Chronic headache and dizziness in the last 3 months; (3) History of hypertension, coronary heart disease, bronchial asthma, acute upper respiratory tract infection, anemia, or decompensation; (4) Have a history of migraine or cluster headache. (5) Have participated in other interventional studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite effecacy outcome (including LLS >=3, or ESQ-III >=0.7, or symptomatic or imaging-detected HACE or HAPE);Acetazolamide-related adverse reactions (including sensory abnormalities, polyuria, and taste disorders);RIPC-related adverse reactions (including subcutaneous bleeding in the upper arm); | — |
Secondary
| Measure | Time frame |
|---|---|
| Louis Lake Score;ESQ-III;symptomatic or imaging-detected HACE or HAPE; | — |
Countries
China
Contacts
Public ContactJian Wang; Jian Yang
Ya'an People's Hospital
Outcome results
None listed